Literature DB >> 30270506

Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma.

Shree Bose1, Joanna Robles2, Chad M McCall3, Anand S Lagoo3, Daniel S Wechsler4, Gary R Schooler5, David Van Mater2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30270506      PMCID： PMC6433376          DOI： 10.1002/pbc.27491

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  14 in total

1.  Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma.

Authors:  Anuhya Kommalapati; Sri Harsha Tella; Ronald S Go; Gaurav Goyal
Journal:  Leuk Lymphoma       Date:  2018-07-22

2.  Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.

Authors:  Jie Xu; Heather H Sun; Christopher D M Fletcher; Jason L Hornick; Elizabeth A Morgan; Gordon J Freeman; F Stephen Hodi; Geraldine S Pinkus; Scott J Rodig
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

Review 3.  Histiocytic sarcoma : an updated literature review based on the 2008 WHO classification.

Authors:  Emiko Takahashi; Shigeo Nakamura
Journal:  J Clin Exp Hematop       Date:  2013

4.  Successful treatment of pediatric histiocytic sarcoma using abbreviated high-risk leukemia chemotherapy.

Authors:  Jessica L Heath; Shelly E Burgett; Ana M Gaca; Ronald Jaffe; Daniel S Wechsler
Journal:  Pediatr Blood Cancer       Date:  2014-05-29       Impact factor: 3.167

5.  Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes.

Authors:  Anuhya Kommalapati; Sri Harsha Tella; Martin Durkin; Ronald S Go; Gaurav Goyal
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

6.  Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Authors:  Sophie Voruz; Anne Cairoli; Olaia Naveiras; Laurence de Leval; Edoardo Missiaglia; Krisztian Homicsko; Olivier Michielin; Sabine Blum
Journal:  Haematologica       Date:  2017-11-02       Impact factor: 9.941

7.  Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.

Authors:  Jean Donadieu; Frederic Bernard; Max van Noesel; Mohamed Barkaoui; Odile Bardet; Rosella Mura; Maurizio Arico; Christophe Piguet; Virginie Gandemer; Corinne Armari Alla; Niels Clausen; Eric Jeziorski; Anne Lambilliote; Sheila Weitzman; Jan Inge Henter; Cor Van Den Bos
Journal:  Blood       Date:  2015-07-20       Impact factor: 22.113

8.  Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab.

Authors:  Neerav Shukla; Rachel Kobos; Thomas Renaud; Julie Teruya-Feldstein; Anita Price; Linda McAllister-Lucas; Peter Steinherz
Journal:  Cancer       Date:  2011-12-13       Impact factor: 6.860

9.  Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.

Authors:  Mrinal M Gounder; David B Solit; William D Tap
Journal:  N Engl J Med       Date:  2018-05-17       Impact factor: 91.245

10.  Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.

Authors:  Adam Diehl; Mark Yarchoan; Alex Hopkins; Elizabeth Jaffee; Stuart A Grossman
Journal:  Oncotarget       Date:  2017-12-14
View more
  6 in total

Review 1.  Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms.

Authors:  Gaurav Goyal; Denise Lau; Alison M Nagle; Robert Vassallo; Karen L Rech; Jay H Ryu; Caroline J Davidge-Pitts; W Oliver Tobin; Matthew J Koster; N Nora Bennani; Mithun V Shah; Minetta C Liu; Ronald S Go
Journal:  Blood       Date:  2019-01-29       Impact factor: 22.113

2.  Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.

Authors:  Jennifer A Lenz; Charles-Antoine Assenmacher; Victoria Costa; Katie Louka; Suzanne Rau; Nicholas S Keuler; Paul J Zhang; Robert G Maki; Amy C Durham; Enrico Radaelli; Matthew J Atherton
Journal:  Cancer Immunol Immunother       Date:  2021-08-20       Impact factor: 6.968

3.  Application of PD-L1 blockade in refractory histiocytic sarcoma: A case report.

Authors:  Osamu Imataki; Makiko Uemura; Haruyuki Fujita; Norimitsu Kadowaki
Journal:  Mol Clin Oncol       Date:  2022-07-15

4.  A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab.

Authors:  Yu Furui; Takashi Kurata; Kazutoshi Komori; Eriko Uchida; Yosuke Miyairi; Akihiro Chiba; Yoshifumi Ogiso; Kazuo Sakashita
Journal:  Int Cancer Conf J       Date:  2022-06-30

5.  Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab.

Authors:  Mee-Young Lee; Carolina Bernabe-Ramirez; Daniel C Ramirez; Robert G Maki
Journal:  BMJ Case Rep       Date:  2020-04-22

6.  Case Report: A PD-L1-Positive Patient With Pleomorphic Rhabdomyosarcoma Achieving an Impressive Response to Immunotherapy.

Authors:  Jiayong Liu; Peijie Liu; Fuyu Gong; Youhui Tian; Xiaochen Zhao
Journal:  Front Immunol       Date:  2022-03-17       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.